CardiovascularResearch Chemical

SS-31

Also known as: Elamipretide, Bendavia, MTP-131, Szeto-Schiller peptide 31

Mitochondria-targeting peptide — protects cellular energy production in heart, muscle, and kidney.

Subcutaneous injection Intravenous (clinical trials)

Molecular structure image coming soon

Research use only. Phase III trials ongoing. Not FDA-approved for any indication as of 2025.

Overview

SS-31 (Elamipretide) is a cell-permeable peptide that targets the inner mitochondrial membrane, where it stabilizes cardiolipin — a phospholipid critical for electron transport chain efficiency. It has shown remarkable protective effects in cardiac ischemia-reperfusion injury, heart failure, and renal conditions. Currently in Phase III clinical trials for heart failure with reduced ejection fraction.

Mechanism of Action

SS-31 concentrates in the inner mitochondrial membrane and interacts with cardiolipin, preventing its oxidation and maintaining the structure of electron transport chain supercomplexes. This reduces reactive oxygen species (ROS) production, maintains ATP synthesis, and prevents mitochondrial membrane permeability transition pore (mPTP) opening during cellular stress.

Use Cases

  • Heart failure protection and treatment
  • Cardiac ischemia-reperfusion injury
  • Chronic kidney disease (Phase II data)
  • Muscle weakness and fatigue (mitochondrial)
  • Age-related mitochondrial dysfunction
  • Exercise performance and recovery

Research Summary

Phase II PROGRESS-HF trial showed significant improvements in 6-minute walk distance in heart failure patients. Phase III HEART-FID trial of elamipretide ongoing. Multiple Phase I/II trials in cardiac surgery, renal disease, and mitochondrial myopathy. Landmark research from Hazel Szeto at Weill Cornell.

Typical Dosing

Clinical trials: 40 mg/day subcutaneous. Research protocols: 0.01–10 mg/kg. Dosing varies significantly by indication.

Administration

Subcutaneous injectionIntravenous (clinical trials)

Research Chemical

Research use only. Phase III trials ongoing. Not FDA-approved for any indication as of 2025.

Related Peptides

Verified Sources for SS-31

Browse all →

No verified sources listed yet

Are you a verified supplier of SS-31? Get listed and appear here.

Get Listed